MedTrace Logo

Evaluation of Two Different Non-invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions

NCT00294320 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-02-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the performance of two techniques to monitor the clearance of AK lesions when treated with Aldara 5% cream.

Conditions

  • Actinic Keratosis

Interventions

DRUG

Aldara (Imiquimod)

250mg of Imiquimod cream for application once daily 3 times per week.

OTHER

Vehicle cream

250mg vehicle cream for application once daily 3 times per week.

Sponsors & Collaborators

  • MEDA Pharma GmbH & Co. KG

    lead INDUSTRY

Principal Investigators

  • Jean-Paul Ortonne, Professor · CPCAD, Hopital L'Archet 2

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2007-01-31
Completion
2007-01-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00294320 on ClinicalTrials.gov